Anti-CGRP Monoclonal Antibodies in Chronic Migraine: A Position Statement of the Brazilian Academy of Headache and Orofacial Pain.

Chronic migraine (CM) is a serious condition affecting many people. It often comes with other health issues and is hard to treat. Recent treatments include anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs). However, there is limited information on how these treatments work in Latin America. To gather insights, experts surveyed 21 Brazilian headache specialists. They answered 49 questions about their experiences with CM and treatment options. The survey looked at how common medication-overuse headache (MOH) is among patients. It also evaluated the effectiveness of two CGRP mAbs: fremanezumab and galcanezumab. The specialists reached a consensus when at least 80% agreed on a topic. This research aims to provide guidance on using these new treatments effectively for patients suffering from chronic migraine in Brazil. The findings may help improve care for those with this challenging condition. Clinical relevance: This research highlights the potential of CGRP mAbs for chronic migraine treatment, guiding clinicians in managing this complex condition effectively.